Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported resultsCAMBRIDGE, Mass.,…
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with…
Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile…
TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across…
CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor…
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double…
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer…
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression,…
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on…
Special Shareholder Meeting to be Held in July 2023PHILADELPHIA and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- BriaCell…